[go: up one dir, main page]

MXPA05013478A - Combinaciones terapeuticas. - Google Patents

Combinaciones terapeuticas.

Info

Publication number
MXPA05013478A
MXPA05013478A MXPA05013478A MXPA05013478A MXPA05013478A MX PA05013478 A MXPA05013478 A MX PA05013478A MX PA05013478 A MXPA05013478 A MX PA05013478A MX PA05013478 A MXPA05013478 A MX PA05013478A MX PA05013478 A MXPA05013478 A MX PA05013478A
Authority
MX
Mexico
Prior art keywords
dysmenorrhoea
treatment
receptor antagonists
vasopressin receptor
pde inhibitors
Prior art date
Application number
MXPA05013478A
Other languages
English (en)
Inventor
Piet Hadewijn Van Der Graaf
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0313363A external-priority patent/GB0313363D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA05013478A publication Critical patent/MXPA05013478A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen las combinaciones sinergicas de antagonistas de la familia de receptores de la vasopresina con inhibidores de la PDE.
MXPA05013478A 2003-06-10 2004-06-01 Combinaciones terapeuticas. MXPA05013478A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0313363A GB0313363D0 (en) 2003-06-10 2003-06-10 Therapeutic combinations
US48426603P 2003-06-30 2003-06-30
PCT/IB2004/001848 WO2004108138A1 (en) 2003-06-10 2004-06-01 Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea

Publications (1)

Publication Number Publication Date
MXPA05013478A true MXPA05013478A (es) 2006-03-09

Family

ID=33512697

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013478A MXPA05013478A (es) 2003-06-10 2004-06-01 Combinaciones terapeuticas.

Country Status (8)

Country Link
US (1) US20050049255A1 (es)
JP (1) JP2006527257A (es)
AR (1) AR044648A1 (es)
BR (1) BRPI0411347A (es)
CA (1) CA2528975A1 (es)
MX (1) MXPA05013478A (es)
TW (1) TW200503667A (es)
WO (1) WO2004108138A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119088B2 (en) * 2003-02-19 2006-10-10 Pfizer Inc. Triazole compounds useful in therapy
GB0325021D0 (en) * 2003-10-27 2003-12-03 Pfizer Ltd Therapeutic combinations
JP4879977B2 (ja) * 2005-06-10 2012-02-22 ドン・ア・ファーム・カンパニー・リミテッド ピラゾロピリミジノン誘導体を含む肝疾患の予防及び治療剤
EP1909576A4 (en) 2005-07-29 2010-09-01 Concert Pharmaceuticals Inc NEW PHARMACEUTICAL COMPOUNDS
EP2010542B1 (en) 2006-04-12 2012-01-25 Vertex Pharmaceuticals Incorporated 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridines as plk1 protein kinase inhibitors for the treatment of proliferative disorders
US20090221703A1 (en) * 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) * 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
MX377501B (es) 2007-06-04 2025-03-10 Techfields Inc Profarmacos de nsaias con el piel y membranas con indices de penetracion muy altos y nuevos usos medicinales.
AU2009322112B2 (en) 2008-12-04 2016-12-15 Chongxi Yu High penetration compositions and their applications
SG179206A1 (en) 2009-09-25 2012-04-27 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
MX2012003476A (es) 2009-09-25 2012-06-19 Vertex Pharma Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa.
KR20220130239A (ko) 2012-01-18 2022-09-26 테크필즈 파마 코., 엘티디. 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물
CN102766674A (zh) * 2012-07-25 2012-11-07 辉源生物科技（上海）有限公司 食蟹猴抗利尿激素受体v1a拮抗剂筛选平台的建立
WO2014186843A1 (en) * 2013-05-23 2014-11-27 Newcastle Innovation Limited Targeted delivery of drugs to the myometrium
PT3177624T (pt) 2014-08-06 2019-07-11 Pfizer Compostos de imidazopiridazina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786486B3 (fr) * 1998-11-16 2000-12-08 Sanofi Sa Procede de preparation du (2s)-1-[(2r,3s)-5-chloro-3-(2- chlorophenyl)-1-(3,4-dimethoxy benzenesulfonyl)-3-hydroxy- 2,3-dihydro-1h-indole-2-carbonyl]pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6831074B2 (en) * 2001-03-16 2004-12-14 Pfizer Inc Pharmaceutically active compounds
US6900200B2 (en) * 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US7745630B2 (en) * 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators

Also Published As

Publication number Publication date
BRPI0411347A (pt) 2006-07-11
TW200503667A (en) 2005-02-01
AR044648A1 (es) 2005-09-21
JP2006527257A (ja) 2006-11-30
US20050049255A1 (en) 2005-03-03
WO2004108138A1 (en) 2004-12-16
CA2528975A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
ZA200701656B (en) Humanized anti-cment antagonists
MXPA05013478A (es) Combinaciones terapeuticas.
WO2005107726A3 (en) Method for the treatment of back pain
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
PT1899334E (pt) Compostos de naftiridina
MX2007006066A (es) Inhibidores de jnk para el tratamiento de lesiones del snc.
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
EP1740183B8 (en) Novel use for pde5 inhibitors
MY137620A (en) Therapeutic treatment
TW200508233A (en) Chk-1 inhibitors
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
HUP0300990D0 (en) Synergistic combination for the prophylaxis and treatment of diabetes
PL1740200T3 (pl) IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią
UA91988C2 (ru) Фармацевтическая композиция на основе антагонистов nk2 для применения в педиатрии
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
UA6918U (en) Use of fine montmorillonite green clay from ordzhonikidze deposit for stimulation of blood circulation and inhibition of inflammation
UA6623U (en) Method for increasing therapeutic efficacy of clays
TW200635902A (en) Methods and formulations
ZA200605653B (en) Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours

Legal Events

Date Code Title Description
FA Abandonment or withdrawal